The Effect of PDE4 Inhibitor on LPS-Induced Osteoclastogenesis

LPS의 파골세포 분화 유도에 미치는 PDE4 저해제의 증강효과

  • No, A-Long-Sae-Mi (College of Pharmacy, Sookmyung Women's University) ;
  • Chen, Ling (College of Pharmacy, Sookmyung Women's University) ;
  • Yim, Mi-Jung (College of Pharmacy, Sookmyung Women's University)
  • Published : 2008.02.29

Abstract

To determine the regulatory roles of PDE4 inhibitor on LPS-induced osteoclastogenesis, we investigated the effect of a PDE4 inhibitor on osteoclast formation in the presence of LPS. A specific PDE4 inhibitor, rolipram, increased LPS-induced osteoclast formation in cocultures. To verify that whether rolipram acts indirectly on osteoblasts, we investigated the TRANCE and COX-2 mRNA expression levels in osteoblasts. Treatment of rolipram increased the expression of TRANCE and COX-2 mRNA in osteoblasts stimulated by LPS. On the contrary, rolipram did not augment the number of osteoclasts differentiated from bone marrow cells by LPS. In conclusion, the stimulation of LPS-induced osteoclast formation by the PDE4 inhibitor are attributable to its indirect effect on osteoblasts, not to their direct effect on bone marrow-derived osteoclast precursors.

Keywords

References

  1. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J. and Suda, T. : Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600 (1988)
  2. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345 (1999)
  3. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S. 3rd, Frankel, W. N., Lee, S. Y. and Choi, Y. : TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun Nterminal kinase in T cells. J. Biol. Chem. 272, 25190 (1997)
  4. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T. : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597 (1998)
  5. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165 (1998)
  6. Nair, S. P., Meghji, S., Wilson, M., Reddi, K., White, P. and Henderson, B. : Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun. 64, 2371 (1996)
  7. Wang, P. L. and Ohura, K. : Porphyromonas gingivalis lipopolysaccharide signaling in gingival fibroblasts-CD14 and Toll-like receptors. Crit. Rev. Oral. Biol. Med. 13, 132 (2002)
  8. Coon, D., Gulati, A., Cowan, C. and He, J. : The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption. J. Endod. 33, 432 (2007)
  9. Sakuma, Y., Tanaka, K., Suda, M., Komatsu, Y., Yasoda, A., Miura, M., Ozasa, A., Narumiya, S., Sugimoto, Y., Ichikawa, A., Ushikubi, F. and Nakao, K. : Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect Immun. 68, 6819 (2000)
  10. Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M. and Chihara, K. : Prostaglandin $E_2$ stimulates osteoclastlike cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J. Bone Miner. Res. 11, 62 (1996)
  11. Park, H., Young Lee, S., Lee, D. S. and Yim, M. : Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts. Biochem. Biophys. Res. Commun. 354, 178 (2007)
  12. Essayan, D. M. : Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671 (2001) https://doi.org/10.1067/mai.2001.117052
  13. Bender, A. T. and Beavo, J. A. : Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488 (2006)
  14. Jin, S. L., Lan, L., Zoudilova, M. and Conti, M. : Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J. Immunol. 175, 1523 (2005)
  15. Lagente, V., Martin-Chouly, C., Boichot, E., Martins, M. A. and Silva, P. M. : Selective PDE4 inhibitors as potent antiinflammatory drugs for the treatment of airway diseases. Mem. Inst. Oswaldo. Cruz. 100, Suppl 1:131 (2005)
  16. Suda, K., Udagawa, N., Sato, N., Takami, M., Itoh, K., Woo, J. T., Takahashi, N. and Nagai, K. : Suppression of osteoprotegerin expression by prostaglandin $E_2$ is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 172, 2504 (2004)
  17. Itoh, K., Udagawa, N., Kobayashi, K., Suda, K., Li, X., Takami, M., Okahashi, N., Nishihara, T. and Takahashi, N. : Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J. Immunol. 170, 3688 (2003)
  18. Suda, K., Woo, J. T., Takami, M., Sexton, P. M. and Nagai, K. : Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL. J. Cell Physiol. 190, 101 (2002)
  19. Yao, W., Tian, X. Y., Chen, J., Setterberg, R. B., Lundy, M. W., Chmielzwski, P., Froman, C. A. and Jee, W. S. : Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J. Musculoskelet Neuronal Interact. 7, 119 (2007)